Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Nov 19;23(6):347–356. doi: 10.1002/jcla.20324

Endothelin‐1, big endothelin‐1, and nitric oxide in patients with chronic renal disease and hypertension

Ivanka Mikulić 1,✉, József Petrik 2, Krešimir Galešić 3, Željko Romić 3, Ivana Čepelak 2, Monika Zeljko‐Tomić 1
PMCID: PMC6648951  PMID: 19927348

The content is available as a PDF (148.3 KB).

REFERENCES

  • 1. Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997;6:1578–1584. [DOI] [PubMed] [Google Scholar]
  • 2. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761–776. [DOI] [PubMed] [Google Scholar]
  • 3. Jaber BL, Madias NE. Progression of chronic kidney disease: Can it be prevented or arrested? Am J Med 2005;118:1323–1330. [DOI] [PubMed] [Google Scholar]
  • 4. Parmar MS. Chronic renal disease. BMJ 2002;325:85–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Rabelink TJ, Kaasiager KAH, Stroes ESG, Koomans HA. Endothelin in renal pathophysiology: From experimental to therapeutic application. Kidney Int 1996;50:1827–1833. [DOI] [PubMed] [Google Scholar]
  • 6. Emoto N, Yanagisawa M. Endothelin‐converting enzyme‐2 is a membrane‐bound, phosphoramidone‐sensitive metalloproteinase with acidic pH optimum. J Biol Chem 1995;270:15262–15268. [DOI] [PubMed] [Google Scholar]
  • 7. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J. Mechanisms of big endothelin‐1‐induced diuresis and natriuresis: Role of ETB receptors. Hypertension 2000;35:732–739. [DOI] [PubMed] [Google Scholar]
  • 8. Rabelink TJ, Stroes ESG, Bouter KP, Morrison P. Endothelin blockers and renal protection: A new strategy to prevent end‐organ damage in cardiovascular disease? Cardiovasc Res 1998;39:543–549. [DOI] [PubMed] [Google Scholar]
  • 9. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin‐1. Int J Cardiol 2000;72:175–186. [DOI] [PubMed] [Google Scholar]
  • 10. Sofia M, Maniscalco M, Celentano L, et al. Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2001;14:321–327. [DOI] [PubMed] [Google Scholar]
  • 11. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004;53:2060–2066. [DOI] [PubMed] [Google Scholar]
  • 12. Pollock DM. Renal endothelin in hypertension. Curr Opin Nephrol Hypertens 2000;9:157–164. [DOI] [PubMed] [Google Scholar]
  • 13. Hand MF, Haynes WG, Webb DJ. Reduced endogenous endothelin‐1‐mediated vascular tone in chronic renal failure. Kidney Int 1999;55:613–620. [DOI] [PubMed] [Google Scholar]
  • 14. Goddard J, Johnston NR, Hand MF, et al. Endothelin‐A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation 2004;109:1186–1193. [DOI] [PubMed] [Google Scholar]
  • 15. Merta M, Reiterova J, Ryšava R, et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 2003;52:433–437. [PubMed] [Google Scholar]
  • 16. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001;37:21–24. [DOI] [PubMed] [Google Scholar]
  • 17. Zoja C, Benigni A, Camozzi D, et al. Combining lisinopril and l‐arginine slows disease progression and reduces endothelin‐1 in passive Heymann nephritis. Kidney Int 2003;64:857–863. [DOI] [PubMed] [Google Scholar]
  • 18. Ignarro IJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system. J Cardiovasc Pharmacol 1999;34:879–876. [DOI] [PubMed] [Google Scholar]
  • 19. Sharma SP. Nitric oxide and the kidney. Indian J Nephrol 2004;14:77–84. [Google Scholar]
  • 20. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001;16:60–62. [DOI] [PubMed] [Google Scholar]
  • 21. MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol 1994;5:1057–1065. [DOI] [PubMed] [Google Scholar]
  • 22. Seccia TM, Maiolino G, Pessina AC, Rossi GP. The molecular basis of the interplay between endothelin‐1 and nitric oxide and its relevance for atherosclerosis and arterial and pulmonary hypertesion. Vasc Dis Prevention 2005;2:53–66. [Google Scholar]
  • 23. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000;35:1237–1241. [DOI] [PubMed] [Google Scholar]
  • 24. Liu Z, Wildhirt SM, Weismuller S, et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Atherosclerosis 1998;140:1–14. [DOI] [PubMed] [Google Scholar]
  • 25. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999;26:269–271. [DOI] [PubMed] [Google Scholar]
  • 26. Aiello S, Remuzzi G, Noris M. Nitric oxide/endothelin balance after nephron reduction. Kidney Int 1998;53:63–67. [PubMed] [Google Scholar]
  • 27. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: Clinical and research use. Ann Clin Biochem 2000;37:608–626. [DOI] [PubMed] [Google Scholar]
  • 28.Editorial. Nitric oxide determinations: Much ado about NO‐thing? Clin Chem 1997;43:553–556. [PubMed] [Google Scholar]
  • 29. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 1994;158:485–494. [DOI] [PubMed] [Google Scholar]
  • 30. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin A‐receptor antagonist‐mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin‐B receptor blockade. Circulation 1998;97:752–756. [DOI] [PubMed] [Google Scholar]
  • 31. Ahlborg G, Lundberg JM. Nitric oxide–endothelin‐1 interactions in humans. J Appl Physiol 1997;82:1593–1600. [DOI] [PubMed] [Google Scholar]
  • 32. Abassi ZA, Klein H, Golomb E, et al. Urinary endothelin: A possible biological marker of renal damage. Am J Hypertens 1993;6:1046–1054. [DOI] [PubMed] [Google Scholar]
  • 33. Brown M, Chou SJ, Porush JG. Endothelins and kidney disease. Nephron 1996;73:375–382. [DOI] [PubMed] [Google Scholar]
  • 34. Abassi ZA, Tate JE, Golomb E, et al. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992;20:89–95. [DOI] [PubMed] [Google Scholar]
  • 35. King AJ, Brenner BM, Anderson S. Endothelin: A potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989;256:1051–1058. [DOI] [PubMed] [Google Scholar]
  • 36. Simonsom MS, Wan S, Menne P. Endothelin stimulates phospholipase C, Na+/H+ exchange, c‐fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708–712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Benigni A, Zoja C, Corna D, et al. Specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440–444. [DOI] [PubMed] [Google Scholar]
  • 38. De Mattia G, Cassone‐Faldetta M, Bellini C, et al. Role of plasma and urinary endothelim‐1 in early diabetic and hypertensive nephropathy. Am J Hypertens 1998;11:983–988. [DOI] [PubMed] [Google Scholar]
  • 39. Schnackenberg C, Patel AR, Kirchner KA, Granger JP. Nitric oxide, the kidney and hypertension. Clin Exp Pharmacol Physiol 1997;24:600–606. [DOI] [PubMed] [Google Scholar]
  • 40. Rabelink TJ, Bakris GL. The renin‐angiotensin system in diabetic nephropathy: The enothelial connection. Miner Electrolyte Metab 1998;24:381–388. [DOI] [PubMed] [Google Scholar]
  • 41. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306–310. [DOI] [PubMed] [Google Scholar]
  • 42. Tarquini B, Perfetto F, Tarquini R, Cornelissen G, Halberg F. Endothelin‐1 chronome indicates diabetic and vascular disease chronorisk. Peptides 1997;18:119–132. [DOI] [PubMed] [Google Scholar]
  • 43. Lee YL, Shin SJ, Tsai JH. Increased urinary endothelin‐1‐like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care 1994;17:263–266. [DOI] [PubMed] [Google Scholar]
  • 44. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor‐β in patients with type II diabetes. Diabetes 1997;46:854–859. [DOI] [PubMed] [Google Scholar]
  • 45. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin‐1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934–941. [DOI] [PubMed] [Google Scholar]
  • 46. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003;284:1121–1137. [DOI] [PubMed] [Google Scholar]
  • 47. Kone BC. Localization and regulation of nitric oxide synthase isoforms in the kidney. Semin Nephrol 1999;19:230–241. [PubMed] [Google Scholar]
  • 48. Sugimoto H, Shikata K, Matsuda M, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998;41:1426–1434. [DOI] [PubMed] [Google Scholar]
  • 49. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetic nephropathy. Kidney Int 1997;60:46–53. [PubMed] [Google Scholar]
  • 50. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: Role of NO. Am J Physiol 1993;265:886–895. [DOI] [PubMed] [Google Scholar]
  • 51. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993;43:1306–1312. [DOI] [PubMed] [Google Scholar]
  • 52. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971–1010. [DOI] [PubMed] [Google Scholar]
  • 53. Webb ML, Meek TD. Inhibitors of endothelin. Med Res Rev 1997;17:17–67. [DOI] [PubMed] [Google Scholar]
  • 54. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005;43:19–29. [DOI] [PubMed] [Google Scholar]
  • 55. Hirai Y, Adachi H, Fujiura Y, Hiratsuka A, Enomoto M, Imaziumi T. Plasma endothelin‐1 level is related to renal function and smoking status but not to blood pressure: An epidemiological study. J Hypertens 2004;22:713–718. [DOI] [PubMed] [Google Scholar]
  • 56. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092–3095. [DOI] [PubMed] [Google Scholar]
  • 57. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end‐organ damage in hypertension. Kidney Int 1998;54:14–19. [DOI] [PubMed] [Google Scholar]
  • 58. Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989;1:991–992. [DOI] [PubMed] [Google Scholar]
  • 59. Warrens AN, Cassidy MJD, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol Dial Transplant 1990;5:418–422. [DOI] [PubMed] [Google Scholar]
  • 60. Miyauchi T, Sugishita Y, Yamaguchi I, et al. Plasma concentrations of endothelin‐1 and endothelin‐3 are altered differently in various pathophysiological conditions in humans. J Cardiovasc Pharmacol 1991;17:394–397. [DOI] [PubMed] [Google Scholar]
  • 61. Web DJ, Cockcroft JR. Plasma immunoreactive endothelin in uraemia. Lancet 1989;1:1211. [DOI] [PubMed] [Google Scholar]
  • 62. Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991;260:331–339. [DOI] [PubMed] [Google Scholar]
  • 63. Brooks DP, Contino LC, Storer B, Ohlstein E. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991;104:987–989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354–358. [DOI] [PubMed] [Google Scholar]
  • 65. Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin‐1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307–311. [DOI] [PubMed] [Google Scholar]
  • 66. Dumont Y, D'Amours M, Lebel M, Larivière R. Supplementation with a low dose of l‐arginine reduces blood pressure and endothelin‐1 production in hypertensive uraemic rats. Nephrol Dial Transplant 2001;16:746–754. [DOI] [PubMed] [Google Scholar]
  • 67. Moeslinger T, Spickermann PG. Urea‐induced inducible nitric oxide synthase inhibition and macrophage proliferation. Kidney Int 2001;78:2–8. [DOI] [PubMed] [Google Scholar]
  • 68. Aiello S, Noris M, Remuzzi G. Nitric oxide/l‐arginine in uremia. Miner Electrolyte Metab 1999;25:384–390. [DOI] [PubMed] [Google Scholar]
  • 69. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000;58:1261–1266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Li H, Wallerath T, Münzel T, Förstermann U. Regulation of endothelial‐type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002;7:149–164. [DOI] [PubMed] [Google Scholar]
  • 71. Chalupsky K, Hua C. Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. PNAS 2005;25:9056–9061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium‐dependent vasodilatation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 2000;11:1726–1734. [DOI] [PubMed] [Google Scholar]
  • 73. Hazen SL, Hazen SL, Zhang R, Shen Z. Formation of nitric oxide derived oxidants by myeloperoxidase in monocytes: Pathways for monocyte mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999;85:950–958. [DOI] [PubMed] [Google Scholar]
  • 74. Karet F, Kuc R, Davenport A. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993;44:36–42. [DOI] [PubMed] [Google Scholar]
  • 75. Nambi P, Pullen M, Wu HL, Aiyar N, Ohlstein EH, Edwards RM. Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype‐selective ligands. Endocrinology 1992;131:1081–1086. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES